MediciNova
Clinical trials sponsored by MediciNova, explained in plain language.
A biopharmaceutical company developing treatments for neurological and inflammatory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to tackle fatty liver and diabetes at once Results expected Dec 2026 (estimated)
- Could an old asthma drug slow ALS? new trial aims to find out Results expected Apr 2027 (estimated) 🚀 Make-or-break
-
Could an old asthma drug slow ALS? new trial aims to find out
Disease control OngoingThis clinical trial tests whether ibudilast (MN-166), a drug previously used for asthma, can slow the progression of amyotrophic lateral sclerosis (ALS). The study involves 234 adults with ALS, who will receive either ibudilast or a placebo for 12 months, followed by a 6-month op…
Phase 2/3 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill aims to tackle fatty liver and diabetes at once
Disease control OngoingThis phase 2 trial tests an oral drug called MN-001 (tipelukast) in 40 adults with non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. Participants take either the drug or a placebo daily for 24 weeks. The study measures changes in liver fat and blood fat …
Phase 2 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC